<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01497860</url>
  </required_header>
  <id_info>
    <org_study_id>CNMC-VRL</org_study_id>
    <nct_id>NCT01497860</nct_id>
  </id_info>
  <brief_title>Vinorelbine for Children With Progressive or Recurrent Low-grade Gliomas</brief_title>
  <official_title>Phase 2 Study of Weekly Vinorelbine in Children With Progressive or Recurrent Low-Grade Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eugene Hwang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's National Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether weekly Vinorelbine treatment can shrink
      or slow the growth of pediatric low-grade gliomas that have either returned or are continuing
      to grow.

      Vinorelbine is a semi-synthetic vinca alkaloid that has recently generated interest in
      patients with pediatric low-grade glioma. It has been specifically synthesized to broaden its
      therapeutic spectrum and decrease the neurotoxicity associated with related agents.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Different treatments exist for children with progressive or recurrent low-grade glioma. Each
      has variable efficacy at slowing or reversing growth, and exploration continues into finding
      better-tolerated, more effective treatments.

      Vinorelbine has recently generated interest in stabilizing some pediatric low-grade gliomas.
      It has been fairly well tolerated in both adult and pediatric studies that have examined its
      use in other tumors.

      Objective: To test the efficacy of Vinorelbine in children with pediatric low-grade glioma
      that has returned or continues to grow.

      In this trial, Vinorelbine will be given intravenously once a week for 6 weeks followed by a
      2 week rest (6 of every 8 weeks) for one year. The patients will then be followed for 60
      months. Progression free survival is the primary outcome and defined as the none of the
      following: greater a 20% increase in the sun of the longest diameter of the target lesion, or
      a measurable increase in a non-target lesion, or the appearance of new lesions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>Assessed throughout the study from the first dose of the study drug to the date of progressive disease, death, or 60m.</time_frame>
    <description>IV Vinorelbine (6mg/m2) provided once a week for 6 weeks followed by a 2 week rest (6 of every 8 weeks) for one year. Progression free survival will be monitored for 60 months.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Low-grade Glioma</condition>
  <arm_group>
    <arm_group_label>Vinorelbine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV Vinorelbine (6mg/m2) provided once a week for 6 weeks followed by a 2 week rest (6 of every 8 weeks) for one year. Progression free survival will be monitored for 60 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
    <description>IV Vinorelbine (6mg/m2) provided once a week for 6 weeks followed by a 2 week rest (6 of every 8 weeks) for one year. Progression free survival will be monitored for 60 months.</description>
    <arm_group_label>Vinorelbine</arm_group_label>
    <other_name>Navelbine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: &lt; 18 years

          -  Tumor: Progressive or recurrent low grade glioma, WHO grade 1 or 2 who have failed at
             least one form of 'conventional' non-surgical therapy

          -  Histologic confirmation is required with the exception of optic pathway and brain stem
             gliomas. Patients are not required to have a re-operation at time of recurrence.

          -  Patients with disseminated disease are eligible.

          -  Children with neuro-fibromatosis and optic pathway or brainstem tumors are eligible
             but must have definitive radiologic or clinical evidence of progression

          -  Patients must have evidence of measureable disease

          -  Performance status: Karnofsky or Lansky performance status of &gt;50%

          -  Organ Function:

          -  Adequate bone marrow function (ANC&gt;1000/mm3, platelet count of &gt;75,000/mm3, and
             hemoglobin &gt; 8gm/dL) prior to starting therapy. Hemoglobin may be supported by
             transfusion

          -  Adequate liver function (SGPT/ALT&lt;2.5 times ULN and bilirubin &lt; 1.5 times ULN) prior
             to starting therapy

          -  Prior therapy:

          -  May have had treatment including surgery, chemotherapy, or radiotherapy for any number
             of relapses prior to enrollment

          -  Patients must have received their last fraction of radiotherapy &gt;12 weeks prior to
             starting therapy

          -  Previous Vincristine or Vinblastine exposure is allowable.

        Exclusion Criteria:

          -  No other significant medical illness that in the investigators' opinion cannot be
             adequately controlled with appropriate therapy or would compromise the patient's
             ability to tolerate this therapy

          -  Any other cancer (except non-melanoma skin cancer), unless in complete remission and
             off of all therapy for that disease for a minimum of 3 years.

          -  Patients of childbearing potential must not be pregnant or breast-feeding (vinorelbine
             is a pregnancy category D, no data on excretion in breastmilk)

          -  Patients of childbearing or fathering potential must practice adequate contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eugene Hwang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's National Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>December 16, 2011</study_first_submitted>
  <study_first_submitted_qc>December 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2011</study_first_posted>
  <results_first_submitted>April 22, 2019</results_first_submitted>
  <results_first_submitted_qc>April 22, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 20, 2019</results_first_posted>
  <last_update_submitted>April 22, 2019</last_update_submitted>
  <last_update_submitted_qc>April 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Children's National Research Institute</investigator_affiliation>
    <investigator_full_name>Eugene Hwang</investigator_full_name>
    <investigator_title>Assistant Professor, Pediatric Oncology</investigator_title>
  </responsible_party>
  <keyword>pediatric</keyword>
  <keyword>children</keyword>
  <keyword>glioma</keyword>
  <keyword>low-grade</keyword>
  <keyword>vinorelbine</keyword>
  <keyword>recurrent</keyword>
  <keyword>progressive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vinorelbine</title>
          <description>Patients with recurrent/progressive low-grade glioma, treatment six out of every eight weeks with IV vinorelbine for 12 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vinorelbine</title>
          <description>Patients with recurrent/progressive low-grade glioma, treatment six out of every eight weeks with IV vinorelbine for 12 months. Patients recruited without incidence over a 2 year period.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.5" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival</title>
        <description>IV Vinorelbine (6mg/m2) provided once a week for 6 weeks followed by a 2 week rest (6 of every 8 weeks) for one year. Progression free survival will be monitored for 60 months.</description>
        <time_frame>Assessed throughout the study from the first dose of the study drug to the date of progressive disease, death, or 60m.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vinorelbine</title>
            <description>IV Vinorelbine (6mg/m2) provided once a week for 6 weeks followed by a 2 week rest (6 of every 8 weeks) for one year. Progression free survival will be monitored for 60 months.
Vinorelbine: IV Vinorelbine (6mg/m2) provided once a week for 6 weeks followed by a 2 week rest (6 of every 8 weeks) for one year. Progression free survival will be monitored for 60 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>IV Vinorelbine (6mg/m2) provided once a week for 6 weeks followed by a 2 week rest (6 of every 8 weeks) for one year. Progression free survival will be monitored for 60 months.</description>
          <units>percentage</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.1" lower_limit="14.8" upper_limit="31.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Adverse Events</title>
          <description>Neutropenia - Grade 4 (n=2) Thrombocytopenia - Grade 4 (n=1) Anemia - Grade 3 (n=2) Weight Loss - grade 2 (n=1)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>neutropenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>weight loss</sub_title>
                <description>weight loss &gt;10%</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Associate Professor</name_or_title>
      <organization>Children's National Medical Center</organization>
      <phone>2024765046</phone>
      <email>ehwang@childrensnational.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

